dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Simpson-Yap, Steve |
dc.contributor.author | De Brouwer, Edward |
dc.contributor.author | Kalincik, Tomas |
dc.contributor.author | Rijke, Nick |
dc.contributor.author | Hillert, Jan A. |
dc.contributor.author | Walton, Clare |
dc.contributor.author | Zabalza de Torres, Ana |
dc.contributor.author | Arrambide García, Georgina |
dc.date.accessioned | 2022-03-09T11:57:01Z |
dc.date.available | 2022-03-09T11:57:01Z |
dc.date.issued | 2021-11-09 |
dc.identifier.citation | Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021 Nov 9;97(19):e1870–85. |
dc.identifier.issn | 1526-632X |
dc.identifier.uri | https://hdl.handle.net/11351/7128 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosis múltiple |
dc.language.iso | eng |
dc.publisher | Wolters Kluwer Health |
dc.relation.ispartofseries | Neurology;97(19) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Complicacions |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /complications |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.title | Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/WNL.0000000000012753 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /complicaciones |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1212/WNL.0000000000012753 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Simpson-Yap S] Department of Medicine, and Neuroepidemiology Unit, Melbourne School of Population & Global Health, University of Melbourne, Parkville, Australia. Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia [De Brouwer E] University of Tasmania, Hobart, Australia. ESAT-STADIUS, KU Leuven, Belgium. [Kalincik T] Department of Neurology, Melbourne MS Centre, Royal Melbourne Hospital, Parkville, Australia. [Rijke N, Walton C] MS International Federation, London, UK. [Hillert JA] Department of Clinical Neuroscience, Swedish MS Registry, Stockholm, Sweden. [Zabalza A, Arrambide G] Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34610987 |
dc.identifier.wos | 000713678100016 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |